We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
Lung Therapeutics (LTI) is a biopharmaceutical company developing therapeutics for orphan, unmet needs in lung injury and disease. The Company’s lead drug, LTI-01, is a pro-enzyme for the treatment of Loculated Pleural Effusion (LPE), a severe consequence of pneumonia for which there is no approved pharmacotherapy. In a completed ex-US clinical trial in patients, LTI-01 was demonstrated safe and effective in clearing LPE, resulting in avoidance of surgery and decreased hospitalization. There are no approved drugs for the treatment of LPE. LTI has received US and EU Orphan Drug Designation for LTI-01. The Company’s second drug, LTI-03, is in development for the treatment of idiopathic pulmonary fibrosis (IPF). LTI-03 is a novel peptide addressing a unique mechanism which both promotes epithelial cell survival as well as destruction of fibroblasts. LTI-03 has been proven safe in GLP tox and is ready to enter clinical trials. LTI is raising funding for clinical trials of both drugs.